Nature Reviews Nephrology, Journal Year: 2018, Volume and Issue: 14(8), P. 521 - 534
Published: June 25, 2018
Language: Английский
Kidney International, Journal Year: 2020, Volume and Issue: 98(4), P. S1 - S115
Published: Sept. 30, 2020
The Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Disease (CKD) represents the first KDIGO guideline on this subject. scope includes topics such as comprehensive care, glycemic monitoring and targets, lifestyle antihyperglycemic interventions, approaches to self-management optimal models of care. goal is generate a useful resource clinicians patients by providing actionable recommendations with infographics based rigorous, formal systematic literature review. Another aim propose research areas which there are gaps knowledge. targets broad audience treating diabetes CKD while taking into account implications policy payment. development followed an explicit process evidence review appraisal. Treatment reviews relevant studies, appraisal quality evidence, strength following Grading Recommendations Assessment, Development, Evaluation (GRADE) approach. Limitations discussed future presented.
Language: Английский
Citations
966
Kidney International, Journal Year: 2022, Volume and Issue: 102(5), P. S1 - S127
Published: Oct. 19, 2022
The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Disease (CKD) represents a focused update of the KDIGO 2020 guideline on topic. targets broad audience clinicians treating diabetes and CKD. Topic areas which recommendations are updated include: Chapter 1: Comprehensive care patients with CKD 4: Glucose-lowering therapies type 2 (T2D) Previous chapters Glycemic monitoring (Chapter 2), Lifestyle interventions 3), Approaches to management 5) have been deemed current their content has remained unchanged. Development this followed an explicit process evidence review appraisal. Treatment approaches based systematic reviews relevant studies, appraisal quality strength “Grading Recommendations Assessment, Evaluation” (GRADE) approach. Limitations discussed future research also presented.
Language: Английский
Citations
731
Cell Metabolism, Journal Year: 2019, Volume and Issue: 30(4), P. 784 - 799.e5
Published: Aug. 29, 2019
Language: Английский
Citations
475
Nature Medicine, Journal Year: 2017, Volume and Issue: 23(6), P. 753 - 762
Published: April 24, 2017
Language: Английский
Citations
405
Advanced Drug Delivery Reviews, Journal Year: 2017, Volume and Issue: 129, P. 295 - 307
Published: Dec. 27, 2017
Language: Английский
Citations
244
Nature Reviews Nephrology, Journal Year: 2022, Volume and Issue: 18(9), P. 545 - 557
Published: July 4, 2022
Language: Английский
Citations
226
Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)
Published: June 9, 2022
Abstract Chronic kidney disease (CKD) is a chronic renal dysfunction syndrome that characterized by nephron loss, inflammation, myofibroblasts activation, and extracellular matrix (ECM) deposition. Lipotoxicity oxidative stress are the driving force for loss of including tubules, glomerulus, endothelium. NLRP3 inflammasome signaling, MAPK PI3K/Akt RAAS signaling involves in lipotoxicity. The upregulated Nox expression decreased Nrf2 result directly. injured resident cells release proinflammatory cytokines chemokines to recruit immune such as macrophages from bone marrow. NF-κB JAK-STAT Toll-like receptor cGAS-STING major pathways mediate inflammation inflammatory cells. produce secret great number profibrotic TGF-β1, Wnt ligands, angiotensin II. TGF-β Notch evoke activation promote generation ECM. potential therapies targeted these also introduced here. In this review, we update key lipotoxicity, stress, kidneys with injury, drugs based on latest studies. Unifying will be instrumental advance further basic clinical investigation CKD.
Language: Английский
Citations
225
Nature Reviews Nephrology, Journal Year: 2021, Volume and Issue: 17(8), P. 554 - 568
Published: May 5, 2021
Language: Английский
Citations
163
Theranostics, Journal Year: 2019, Volume and Issue: 9(14), P. 3980 - 3991
Published: Jan. 1, 2019
Rationale: Renal fibrosis is the terminal manifestation of chronic and irreversible renal disease.Effective therapies other than dialysis are extremely limited.In this study, we investigated potential effects targeting elevated interleukin-6 (IL-6) levels in treatment fibrosis.Methods: Fc-gp130 was used to specifically block IL-6 trans-signaling.Unilateral ureteral occlusion (UUO) ischemia reperfusion (IR) mouse models were constructed investigate therapeutic effect on fibrosis.The role trans-signaling phosphorylation signal transducer activator transcription (STAT) 3 regulating fibroblast accumulation extracellular matrix protein deposition evaluated cell experiments models. Results:The kidneys mice with UUO found have soluble receptor (sIL-6R) progression fibrosis.Fc-gp130 attenuated mice, as evidenced by reductions tubular atrophy production protein.Blockade also reduced inflammation levels, immune infiltration, profibrotic cytokines expression tissue, decreased STAT3 tissue.In vitro, induced transforming growth factor (TGF)-β1 fibroblasts.Furthermore, confirmed a model acute kidney injury-chronic disease.Conclusion: Overall, may contribute crucial events development fibrosis, provide novel strategy for fibrosis.
Language: Английский
Citations
150
Acta Pharmacologica Sinica, Journal Year: 2019, Volume and Issue: 41(5), P. 670 - 677
Published: Dec. 5, 2019
Language: Английский
Citations
148